sorafenib has been researched along with thyroxine in 7 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (thyroxine) | Trials (thyroxine) | Recent Studies (post-2010) (thyroxine) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 38,989 | 1,410 | 6,550 |
| Protein | Taxonomy | sorafenib (IC50) | thyroxine (IC50) |
|---|---|---|---|
| Transthyretin | Homo sapiens (human) | 2.1939 | |
| UDP-glucuronosyltransferase 1A1 | Homo sapiens (human) | 5.25 | |
| Solute carrier organic anion transporter family member 4C1 | Homo sapiens (human) | 8 | |
| Bile acid receptor | Homo sapiens (human) | 7.86 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Abdulrahman, RM; Corssmit, EP; Gelderblom, H; Hoftijzer, H; Hovens, GC; Kapiteijn, E; Pereira, AM; Reiners, C; Romijn, JA; Smit, JW; Verburg, E; Verloop, H; Visser, TJ | 1 |
| Bierer, S; Herrmann, E; Hertle, L; Hoffmeister, I; Köpke, T; Papavassilis, P; Riesenbeck, LM; Thielen, B | 1 |
| Cano Megías, M; Carrasco De La Fuente, M; González Albarrán, O; Menacho Román, M; Pérez López, G | 1 |
| Block, MS; Kohli, M | 1 |
| Ahmed, AA; Elnakish, MT; Floyd, K; Janssen, PM; Mohler, PJ; Saad, NS | 1 |
| Beukhof, CM; Bins, S; Chaker, L; de Herder, WW; de Rijke, YB; Mathijssen, RH; Peeters, RP; van Doorn, L; van Heerebeek, R; van Kemenade, FJ; Visser, TJ; Visser, WE | 1 |
1 review(s) available for sorafenib and thyroxine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for sorafenib and thyroxine
| Article | Year |
|---|---|
Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination.
Topics: Aged; Aged, 80 and over; Benzenesulfonates; Carcinoma; Female; Humans; Hypothyroidism; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Pyridines; Sorafenib; Thyroid Neoplasms; Thyrotropin; Thyroxine; Treatment Outcome; Triiodothyronine | 2010 |
5 other study(ies) available for sorafenib and thyroxine
| Article | Year |
|---|---|
Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate; Thyrotropin; Thyroxine; Treatment Outcome; Triiodothyronine | 2011 |
[Management of hypothyroidism secondary to tyrosine kinase inhibitors: description of treatment in three distinct clinical settings].
Topics: Adult; Benzamides; Benzenesulfonates; Carcinoma, Renal Cell; Choristoma; Female; Gastrointestinal Stromal Tumors; Humans; Hypothyroidism; Imatinib Mesylate; Indoles; Kidney Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Piperazines; Pleural Diseases; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Thymus Gland; Thyroxine | 2011 |
Clinical hypothyroidism in a renal cell carcinoma patient treated with sorafenib.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Hypothyroidism; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Thyroxine | 2011 |
The Effect of Sorafenib, Tadalafil and Macitentan Treatments on Thyroxin-Induced Hemodynamic Changes and Cardiac Abnormalities.
Topics: Animals; Blood Pressure; Cardiomyopathies; Disease Models, Animal; Echocardiography; Electrocardiography; Heart Defects, Congenital; Heart Rate; Hemodynamics; Male; Mice; Myocardial Contraction; Niacinamide; Organ Size; Phenylurea Compounds; Pyrimidines; Sorafenib; Sulfonamides; Tadalafil; Thyroxine | 2016 |
Sorafenib-Induced Changes in Thyroid Hormone Levels in Patients Treated for Hepatocellular Carcinoma.
Topics: Aged; Amino Acid Transport Systems, Neutral; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Chlorocebus aethiops; Cohort Studies; COS Cells; Female; Humans; In Vitro Techniques; Liver Neoplasms; Male; Middle Aged; Monocarboxylic Acid Transporters; Niacinamide; Phenylurea Compounds; Prospective Studies; Sorafenib; Symporters; Thyrotropin; Thyroxine; Triiodothyronine | 2017 |